279 related articles for article (PubMed ID: 23727433)
21. Zoledronate Impairs Socket Healing after Extraction of Teeth with Experimental Periodontitis.
Soundia A; Hadaya D; Esfandi N; Gkouveris I; Christensen R; Dry SM; Bezouglaia O; Pirih F; Nikitakis N; Aghaloo T; Tetradis S
J Dent Res; 2018 Mar; 97(3):312-320. PubMed ID: 28954199
[TBL] [Abstract][Full Text] [Related]
22. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
Nicolatou-Galitis O; Razis E; Galiti D; Galitis E; Labropoulos S; Tsimpidakis A; Sgouros J; Karampeazis A; Migliorati C
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):699-706. PubMed ID: 26455289
[TBL] [Abstract][Full Text] [Related]
23. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of BP-ONJ in osteopenic and healthy sheep: comparing ZTE-MRI with µCT.
Voss P; Ludwig U; Poxleitner P; Bergmaier V; El-Shafi N; von Elverfeldt D; Stadelmann V; Hövener JB; Flügge T
Dentomaxillofac Radiol; 2016; 45(4):20150250. PubMed ID: 26846710
[TBL] [Abstract][Full Text] [Related]
25. Effect of bisphosphonates on healing of tooth extraction wounds in infectious osteomyelitis of the jaw.
Yamashita J; Sawa N; Sawa Y; Miyazono S
Bone; 2021 Feb; 143():115611. PubMed ID: 32829042
[TBL] [Abstract][Full Text] [Related]
26. Antiresorptive-Type and Discontinuation-Timing Affect ONJ Burden.
Hadaya D; Soundia A; Gkouveris I; Bezouglaia O; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S
J Dent Res; 2021 Jul; 100(7):746-753. PubMed ID: 33478337
[TBL] [Abstract][Full Text] [Related]
27. Antiresorptives and osteonecrosis of the jaw.
Yamashita J; McCauley LK
J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351
[TBL] [Abstract][Full Text] [Related]
28. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-κB ligand antibody in mice.
Williams DW; Lee C; Kim T; Yagita H; Wu H; Park S; Yang P; Liu H; Shi S; Shin KH; Kang MK; Park NH; Kim RH
Am J Pathol; 2014 Nov; 184(11):3084-93. PubMed ID: 25173134
[TBL] [Abstract][Full Text] [Related]
29. Zoledronate treatment exerts sex-independent effects on bone and dental physicochemical properties in mice jaw necrosis.
Lima-Verde MEQ; de Queiroz Rodrigues MI; Vieira BR; Lima-Verde Neto FTG; Agressott EVH; de Sousa FB; Paschoal AR; de Barros Silva PG; Sousa FB; Mota MRL; Alves APNN
J Bone Miner Metab; 2023 Nov; 41(6):760-771. PubMed ID: 37673837
[TBL] [Abstract][Full Text] [Related]
30. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
[TBL] [Abstract][Full Text] [Related]
31. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis.
Aguirre JI; Akhter MP; Kimmel DB; Pingel JE; Williams A; Jorgensen M; Kesavalu L; Wronski TJ
J Bone Miner Res; 2012 Oct; 27(10):2130-43. PubMed ID: 22623376
[TBL] [Abstract][Full Text] [Related]
32. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
33. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review.
Nicolatou-Galitis O; Kouri M; Papadopoulou E; Vardas E; Galiti D; Epstein JB; Elad S; Campisi G; Tsoukalas N; Bektas-Kayhan K; Tan W; Body JJ; Migliorati C; Lalla RV;
Support Care Cancer; 2019 Feb; 27(2):383-394. PubMed ID: 30353228
[TBL] [Abstract][Full Text] [Related]
34. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats.
Hokugo A; Christensen R; Chung EM; Sung EC; Felsenfeld AL; Sayre JW; Garrett N; Adams JS; Nishimura I
J Bone Miner Res; 2010 Jun; 25(6):1337-49. PubMed ID: 20200938
[TBL] [Abstract][Full Text] [Related]
35. Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition.
Nagaoka Y; Kajiya H; Ozeki S; Ikebe T; Okabe K
J Dent Res; 2015 Apr; 94(4):594-601. PubMed ID: 25535203
[TBL] [Abstract][Full Text] [Related]
36. Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw.
Abtahi J; Agholme F; Sandberg O; Aspenberg P
J Dent Res; 2013 Mar; 92(3):279-83. PubMed ID: 23264610
[TBL] [Abstract][Full Text] [Related]
37. Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw.
Córdova LA; Guilbaud F; Amiaud J; Battaglia S; Charrier C; Lezot F; Piot B; Redini F; Heymann D
J Craniomaxillofac Surg; 2016 Sep; 44(9):1387-94. PubMed ID: 27519659
[TBL] [Abstract][Full Text] [Related]
38. Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
Sonis ST; Watkins BA; Lyng GD; Lerman MA; Anderson KC
Oral Oncol; 2009 Feb; 45(2):164-72. PubMed ID: 18715819
[TBL] [Abstract][Full Text] [Related]
39. Zoledronic acid - related osteonecrosis of the jaws. Experimental model with dental extractions in rats.
Barba-Recreo P; Del Castillo Pardo de Vera JL; García-Arranz M; Yébenes L; Burgueño M
J Craniomaxillofac Surg; 2014 Sep; 42(6):744-50. PubMed ID: 24342733
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
